Rheumatoid Arthritis Treatment Guidelines
Initial Treatment Regimen
- The European League Against Rheumatism (EULAR) recommends starting methotrexate 15-25 mg weekly, escalating to 0.3 mg/kg within 4-6 weeks, plus folic acid supplementation, combined with short-term glucocorticoids (prednisone 5-10 mg daily), with the goal of achieving remission or low disease activity within 6 months 1
- Methotrexate is the anchor drug and should be part of the first treatment strategy for all newly diagnosed RA patients, starting with 15 mg weekly and escalating rapidly to 20-25 mg weekly within 4-6 weeks 1, 2
- Folic acid supplementation should always be prescribed to reduce methotrexate-related adverse effects 1
- Glucocorticoids provide rapid symptom relief while waiting for methotrexate's full effect, and should be tapered and discontinued after 1-2 years due to long-term risks 1, 6
Treatment Target and Monitoring
- The American College of Rheumatology (ACR) and EULAR recommend aiming for sustained remission or low disease activity in every patient, with remission defined as SDAI ≤3.3 or CDAI ≤2.8, and low disease activity defined as SDAI ≤11 or CDAI ≤10 1, 2
- Disease activity should be assessed every 1-3 months until target is achieved, using measures such as tender and swollen joint counts, patient and physician global assessments, ESR, and CRP 1, 8
- If no improvement by 3 months or target not reached by 6 months, therapy should be adjusted 1, 7
Escalation Strategy for Inadequate Response
- For patients without poor prognostic factors, adding sulfasalazine plus hydroxychloroquine (triple therapy) or switching to subcutaneous methotrexate may be considered if target is not achieved within 3-6 months 1, 2
- For patients with poor prognostic factors, adding a biologic DMARD (TNF inhibitor, abatacept, or tocilizumab) to methotrexate or adding a JAK inhibitor to methotrexate may be considered 1